NASDAQ:ALDX
Aldeyra Therapeutics Stock News
$4.16
-0.0500 (-1.19%)
At Close: May 03, 2024
What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Strong Buy Stock
04:00pm, Monday, 22'nd Jun 2020
Aldeyra Therapeutics, Inc. (ALDX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near te
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
02:12pm, Thursday, 18'th Jun 2020
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
Oppenheimer Releases a Buy Rating on Provention Bio (PRVB) - Markets
08:13pm, Monday, 15'th Jun 2020
Oppenheimer analyst Justin Kim assigned a Buy rating to Provention Bio (PRVB – Research Report) today and set a price
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. AD
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that ADX-2191 has been designated an orphan medicinal product by the European Comm
Connor Clark & Lunn Investment Management Ltd. Grows Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)
07:34am, Sunday, 14'th Jun 2020
Connor Clark & Lunn Investment Management Ltd. boosted its stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 11.4% in the first quarter, according to the company in its most recent disclosure with t
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher
12:37am, Thursday, 11'th Jun 2020
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Edited Transcript of ALDX earnings conference call or presentation 7-May-20 12:00pm GMT
10:28pm, Sunday, 07'th Jun 2020
Q1 2020 Aldeyra Therapeutics Inc Earnings Call
Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:ALDX)
06:01am, Sunday, 07'th Jun 2020
Aldeyra progresses with Reproxalap in dry eye disease. Kezar reports strong data for SLE drug candidate. AbbVie posts positive data for RINVOQ.
Aldeyra Therapeutics Reaches Agreement With FDA For Use Of RASP As Objective Sign For Treatment Of Dry Eye Disease
12:01pm, Thursday, 04'th Jun 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun
Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session
01:04pm, Wednesday, 03'rd Jun 2020
Ironwood Pharmaceuticals (IRWD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Aldeyra Therapeutics to Present at the Jefferies Virtual Healthcare Conference
12:00pm, Wednesday, 03'rd Jun 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference
